Related references
Note: Only part of the references are listed.Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
R. Pili et al.
BRITISH JOURNAL OF CANCER (2012)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
John D. Hainsworth et al.
CANCER INVESTIGATION (2011)
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Jaime Coronel et al.
MEDICAL ONCOLOGY (2011)
A Switch from Canonical to Noncanonical Wnt Signaling Mediates Drug Resistance in Colon Cancer Cells
Michael Bordonaro et al.
PLOS ONE (2011)
Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma
Davit Mosashvilli et al.
CANCER SCIENCE (2010)
Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma
Ambrosi Pertia et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2009)
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix
Jon Jones et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo
Jon Jones et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors
Camillo Porta et al.
JOURNAL OF UROLOGY (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
Decreased acetylation of histone H3 in renal cell carcinoma: A potential target of histone deacetylase inhibitors
Kent Kanao et al.
JOURNAL OF UROLOGY (2008)
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma
Yukihiko Kato et al.
CLINICAL CANCER RESEARCH (2007)
Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients
Stephen O. Ikuerowo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
The phosphoinositide 3-kinase/Akt pathway: A new target in human renal cell carcinoma therapy
Carole Sourbier et al.
CANCER RESEARCH (2006)
Concomitant deregulation of HIF1α and cell cycle proteins in VHL-mutated renal cell carcinomas
DJ Atkins et al.
VIRCHOWS ARCHIV (2005)
Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma
T Migita et al.
CANCER (2002)
Share Paper
